Top Tweets for #junshi
🇨🇳 Shanghai #Junshi Biosciences announced that company’s product, recombinant humanized anti-IL-17A monoclonal antibody (#JS005) has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study (study number: JS005-005-III-PsO) for the treatment of moderate to severe plaque psoriasis.
Both the co-primary endpoints and key secondary endpoints showed statistically significant and clinically meaningful improvements. Junshi Biosciences plans to submit the new drug application of this product to the Chinese regulatory authorities in the near future.
https://t.co/cjM6UFWmGI
🇨🇳 #Junshi Biosciences' #toripalimab has been approved in #China for a new indication for 1L treatment of unresectable or metastatic melanoma. This marks the first Chinese homegrown PD-1 mAb approved for 1L immunotherapy of advanced melanoma. The approval is primarily based on positive data from the MELATORCH study (NCT03430297).
It is the 12th indication approved for toripalimab in China.
To date, a total of 12 PD-1 inhibitors have been approved in China, including two imported drugs and 10 domestic ones. However, for 1L immunotherapy of melanoma, previously only Merck’s pembrolizumab had been approved.
🇨🇳 #Junshi Biosciences’ anti-PD-1 antibody, Loqtorzi (toripalimab), has received its 11th approval in China for 1L unresectable or metastatic hepatocellular carcinoma (HCC) in combination with bevacizumab. /1
#JUNSHI Anunció la Aprobación del #TORIPALIMAB Para Tratar en 1.ª Línea #SMALL_CELL_LUNG_CANCER en #CHINA Con una OS DE 14,6 MESES. Hoy Ha Alcanzado un ACUERDO DE COMERCIALIZACIÓN PARA #EUROPA Con #LEO_PHARMA. ¿NUEVA BALA DE PLATA MUNDIAL #SCLC?
https://t.co/bd0tO56w3z
#pharmamar
🇨🇳 #Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe https://t.co/VKWyFImfiJ
1/🇨🇳 #Junshi Biosciences announced that it has entered into a #licensing agreement with the undisclosed licensor. https://t.co/qXnhmuaPte
1/🇨🇳 #Junshi Biosciences announced that the latest data from the Phase II clinical study of #toripalimab in combination with gemcitabine as first-line treatment for cisplatin-intolerant R/M NPC has been published in Cell Reports Medicine. https://t.co/LK7Uc3wG8Q
1/🇨🇳 On Oct 21, #Junshi Biosciences （#TopAlliance） announced the appointment of Dr. Mehul Shah as Vice President of Business Development, responsible for the Business Development Department, reporting to Jianjun ZOU, General Manager and CEO.
@treetree0104 于适和龚🦆他俩可以凑一对給cpf，真的，不是离了什么攻受cp设定不能行吗？请接受以上思路,皆大欢喜。#于龚 #junshi
#junzhe is FAKE，#junshi is real. Please stick together, since they so desperately need a cp partner. They can constantly doi for 10000xxxx hours as cps’ wish.
Construction began on several factory plants and projects in #Shanghai's #Zhangjiang Innovative Medicine Industry Base. Key projects include #Junshi Biosciences' innovative #medicine industry base and #RemeGen Biosciences' global R&D headquarter, with a combined #investment of 5.6 bln yuan.
Once completed, these projects will boost the local #pharmaceutical economy, accelerate regional #biomedical innovation and attract more industry pioneers to the base.
#InvestinShanghai
Junshi Biosciences granted Dr. Reddy's exclusive rights to develop and commercialize Junshi's toripalimab, an anti-PD-1 monoclonal antibody for the treatment of cancer. Junshi will receive up to $728.3M in milestones.
#dealforma #junshi #DrReddy #biopharma
KGBライブ🎤は1年振りそして
物販は約3年振りに参加しました😙
まさかのJUNSHI兄貴❗️が
ゲストで登場🙌
歌だけやなく🎤vsKGBでもなかなか
良い味出してましたな👍
りなちゃん&C-NAちゃんとの
コラボチェキ📷無事にゲット✌️
兄貴男前ですやん😙
#JUNSHI
#ごんごんゴンちゃん
#C-NA
#KちゃんGANGBabys
#Junshi 社と #Coherus 社のPD-1抗体 #toripalimab の肺がん1st Lineでの成功を祝ったが、重要な疑問がある。それは、米国で承認された試験であるか全く不明である上に、FDAがすべて中国国内で実施された臨床試験に基づいた医薬品を承認するのかということだ。
https://t.co/r2Dr3Tk1Eu
#Evaluate
Presentations:
- The Global first Immune Checkpoint Inhibitor Approval in Nasopharyngeal Carcinoma: the Journey of Toripalimab
Dr. Sheng Yao, Deputy General Manager, Junshi Biosciences
@ChineseAntibody #Junshi #Toripalimab #Nasopharyngeal #Carcinoma #immunotherapy #immune
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.8M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.4M followers
KATY PERRY
@katyperry
89M followers
Taylor Swift
@taylorswift13
82.9M followers
Lady Gaga
@ladygaga
74.4M followers
Virat Kohli
@imvkohli
71.9M followers
Kim Kardashian
@kimkardashian
70.4M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.8M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers